Home > Neurology > EAN 2020 > Headache and Pain > Unmet needs and pipeline

Unmet needs and pipeline

Presented By
Prof. Christian Lampl, Headache Medical Center, Austria
EAN 2020
In a presentation about migraine medication, Prof. Christian Lampl (Headache Medical Center, Austria) argued that, despite recent developments, there is still a need for more treatment options for acute migraine. Prof. Lampl gave an overview of the most important compounds currently in development, including ditants, gepants, and antibodies [1]. Triptans are the gold standard for acute migraine treatment, but have class contraindications that limit their use in patients with cardiovascular diseases. Calcitonin gene-related peptide (CGRP) antagonism does not cause vasoconstriction, making it safe for migraine patients who cannot use triptans. CGRP receptor antagonists (gepants) do not have vasoconstrictive properties either; in phase 2 and 3 trials they have demonstrated similar efficacy to triptans, with fewer side effects. Three new gepants (rimegepant, ubrogepant, and atogepant) are still in a developmental stage. Results from phase 2 and 3 trials...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on